Actively Recruiting
Study of DDR Gene Changes to Predict How Advanced Urothelial Cancer Responds to Platinum-Based Chemotherapy
Led by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Updated on 2025-02-11
135
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are assessing whether changes in certain genes involved in DNA repair affect how well patients with advanced urothelial or bladder cancer respond to platinum-based chemotherapy. This prospective study is conducted under medical supervision to better understand the link between these gene alterations and treatment outcomes in metastatic or unresectable urothelial cancers. Participants receive standard platinum-based chemotherapy, such as cisplatin or carboplatin combined with gemcitabine. All patients will have their tumor tissue tested for DNA damage response DDR gene alterations using a specialized genetic test. Those who have stable disease or respond to chemotherapy may then receive maintenance treatment with avelumab every two weeks until the cancer progresses or side effects become unacceptable. During the study, researchers will monitor treatment response, progression-free survival, overall survival, disease control rates, and treatment-related side effects over periods of six to twelve months. Patients will undergo regular assessments including imaging and clinical evaluations to measure outcomes. The study is planned to follow participants from treatment start through one year to gather comprehensive data on how gene alterations impact chemotherapy effectiveness and patient survival.
CONDITIONS
Brief Title
DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer.
Research Team
R
Roberto Iacovelli, Prof
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here